Get started
Author

Natalia V. Zhukova

Observed names: N V Zhukova, N. V Zhukova, N. V. Zhukova, N. Zhukova, N.V. Zhukova, N.V. Zhukova ( Zhukova, N.V. Zhukova () Zhukova, N.V. Zhukova Zhukova, Natalia Zhukova, Zhukova, N.V., Наталья Владимировна Жукова
ORCID: 0000-0002-0619-2205
Observed ORCID: 0000-0002-0619-2205
OpenAlex ID: A5067647492
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
2022 · Paolo A Ascierto, Daniil Stroyakovskiy, et al. · The Lancet Oncology · 123
Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
2017 · Dmitry M. Ponomarenko, Irina D. Klimova, et al. · Oncotarget · 34
PDF
Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
2021 · Kristina V. Orlova, Evgeniy V. Ledin, et al. · Cancers · 18
PDF
The role of surgery (metastasectomy) in advanced BRAF positive melanoma during modern therapy.
2022 · Kristina V. Orlova, Evgeny Ledin, et al. · Journal of Clinical Oncology · 9
Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
2024 · Igor V. Samoylenko, Yulia M. Kolontareva, et al. · Frontiers in Oncology · 5
PDF
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.
2022 · Grant A. McArthur, Ralf Gutzmer, et al. · Journal of Clinical Oncology · 5
The Novel Diagnostic Index Based on HLA-DRB1 Genotype and PD-L1 Expression can Predict Severe irAEs in Patients with Metastatic Melanoma Taking Immune Checkpoint Inhibitors. The Results of the Pilot Study
2022 · N. Zhukova, R. Orlova, et al. · Critical Reviews in Immunology · 5
Laboratory biomarkers of an effective antitumor immune response. Clinical significance.
2021 · A.M. Malkova, V.V. Sharoyko, et al. · Cancer Treatment and Research Communications · 5
PDF
Predictive biomarkers of immune-related adverse events
2022 · Natalia Zhukova, Rashida Orlova, et al. · Voprosy Onkologii · 2
Modern Treatment of Metastatic Melanoma: From Standards to an Individualized Approach in Real Clinical Practice
2018 · N. V. Zhukova, R. V. Orlova, et al. · Research and Practical Medicine Journal · 2
PDF
The prognostic value of systemic inflammatory factors in patient with metastatic gastric cancer.
2017 · Georgy M. Manikhas, Natalia P. Beliak, et al. · Journal of Clinical Oncology · 2
Changes in clinical guidelines of 2023 and 2025 on treatment of cutaneous and mucosal melanoma
2025 · I. V. Samoylenko, Ya. V. Belenkaya, et al. · Surgery and Oncology · 1
PDF
The predictive potential of autoimmune-inflammatory syndrome induced by adjuvants (ASIA) criteria to assess the risk of adverse events and efficacy of immune checkpoint inhibitor therapy
2022 · Natalia Zhukova, Rashida Orlova, et al. · Immunologic Research · 1
Pathological regression as an indicator of the effectiveness of perioperative FLOT/FOLFOX in patients with resectable gastric cancer
2022 · N.P. Belyak Belyak, R.V. Orlova Orlova, et al. · Фарматека · 1
New diagnostic index for prediction of severe irAEs in patients with metastatic melanoma taking checkpoint inhibitors.
2022 · Natalia V. Zhukova, Rashida Orlova, et al. · Journal of Clinical Oncology · 1
Clinical and pathogenetic relationship between IL-1β and IL-8 in melanoma
2022 · Anna Malkova, Rashida Orlova, et al. · Research Square · 1
PDF
Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy
2022 · Rashida Orlova, Natalia Zhukova, et al. · Cancer Treatment and Research Communications · 1
PDF
Limitations and opportunities of cancer treatment in the COVID-19 pandemic
2021 · R. V. Orlova, E. A. Kaledina, et al. · Meditsinskiy sovet = Medical Council · 1
PDF
Interleukin-1-beta concentration and neutrophil-lymphocyte ratio as possible predicting biomarkers of response to therapy with checkpoint inhibitors.
2021 · Rashida Orlova, Natalia V. Zhukova, et al. · Journal of Clinical Oncology · 1
Trastuzumab + FOLFOX6/FLOT as perioperative therapy for HER2-positive resectable gastric cancer and cardioesophageal transition: RussTrastPraсtik study (interim analysis)
2021 · R. V. Orlova, N. P. Belyak, et al. · Medical alphabet · 1
Changing HER2-status of the primary gastric tumor after neoadjuvant trastuzumab-based therapy.
2020 · Rashida Orlova, Natalia P. Beliak, et al. · Journal of Clinical Oncology · 1
Is it possible to effectively treat second-line gastric cancer, given the prognosis factors?
2019 · Georgy M. Manikhas, Rashida Orlova, et al. · Journal of Clinical Oncology · 1
Клінічний випадок рецидивуючого паротиту в дитини. Обговорення причин
2018 · V.V. Mavrutenkov, Z.O. Chykarenko, et al. · CHILD`S HEALTH · 1
PDF
Volume and character of laboratory researches at hospitalization concerning reumatical arthritis
2011 · Nadezhda Valer'evna Zhukova, N V Zhukova · I P Pavlov Russian Medical Biological Herald · 1
PDF
Type 1 diabetes mellitus during immune checkpoint inhibitor therapy in cancer patients
2026 · R. V. Orlova, I. A. Gerk, et al. · Clinical Case in Oncology
PDF
Works count: 68
Citation count: 223
H-index: 5
I10-index: 3
Year
Topic
Type